Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit

Hims & Hers shares plunged 16.03% to $19.33 on Monday (and are down 26.89% over five days) after Novo Nordisk filed suit seeking to block sales of compounded copies of its patented GLP-1 drugs and following an FDA move to crack down on non‑FDA‑approved compounds; trading volume hit 143.5 million shares, roughly 688% above the three‑month average. The company has withdrawn its planned discounted semaglutide pill and reiterated a pivot toward other conditions and AI health capabilities, but the legal and regulatory developments materially raise execution and revenue risk for the telehealth player. Hims & Hers IPO'd in 2019 and has risen 97% since listing, yet the near‑term outlook now hinges on litigation outcomes and regulatory enforcement around compounded GLP‑1 therapies.

Analysis

Market structure: The HIMS sell-off (−16% today, −26.9% over 5 days; 143.5M shares vs 18.2M avg, +688% vol) transfers near-term pricing power back to branded GLP‑1 makers (Novo Nordisk) and large, regulated pharmacies while compressing valuations of DTC telehealth/online‑pharmacy peers (AMWL, TDOC). Reduced supply of cheap compounded semaglutide increases branded demand and allows incumbents to defend pricing; expect elevated cross‑asset volatility (equity IV up, modest safe‑haven bid in short‑dated Treasuries, minimal FX/commodity moves).

Risk assessment: Tail risks include a preliminary injunction banning compounded GLP‑1 sales (30–90 days) or widescale FDA enforcement cascading into class actions and state AG suits; hostile outcomes could wipe >30–50% of HIMS near‑term revenue tied to these products. Immediate risk (days): liquidity/IV spikes; short term (weeks–months): lawsuit filings, FDA guidance; long term (6–24 months): success of HIMS pivot to AI/other prescriptions determines survival. Watch for API supply disruptions and insurer coverage changes as hidden dependencies.

Trade implications: Prefer volatility‑driven hedges now — options to express conviction and pair trades to neutralize sector beta. Tactical: use short equity and put exposure to HIMS for 1–3 month windows while rotating capital into large‑cap pharma (NVO) via 9–12 month call spreads; trim smaller telehealth/online pharmacy beta (AMWL, TDOC) and increase defensive healthcare allocations.

Contrarian angles: The market likely overprices permanent impairment; if litigation limits relief to compounding (not core subscription services), HIMS could recover within 6–12 months as recurring revenue reasserts value. Historical parallel: regulatory shocks (e.g., early telehealth patchwork rules) caused 30–60% panics but survivors that diversified revenue rebounded; downside is a full IP loss which would justify a 50%+ re‑rating.

Key Decisions for Investors

• Establish a 1.5% portfolio short position in HIMS (NYSE:HIMS) on any rally above $21.50; set a profit target of $12–$13 (~35–40% downside) and a hard stop at 15% above entry. Rationale: high litigation/FDA risk with elevated IV and clear pathway to revenue impairment within 90 days.
• Buy 60‑day ATM puts on HIMS sized to 0.75% portfolio notional (or equivalent delta exposure) to hedge near‑term volatility; take profits on a 50% option premium move or if a preliminary injunction is denied. Use options to limit capital at risk given fat tails in legal outcomes.
• Initiate a 2% portfolio long in Novo Nordisk (NVO) via a 9–12 month call spread (buy ~5% OTM / sell ~20% OTM) to capture IP/repricing upside from enforcement; size at ~1.25× the HIMS short notional for asymmetric payoff and sector hedge.
• Reduce exposure to small telehealth/online‑pharmacy names (trim AMWL, TDOC by 25–40% within the next 10 trading days) and redeploy proceeds into large‑cap pharma/healthcare services (increase NVO and defensive healthcare weight by 3–5%). Rationale: regulatory uncertainty will compress small‑cap multiples more than large incumbents.